Replies to post #245030 on Biotech Values

[DewDiligence]

EXAS claims Cologuard 2.0 superiority_to_existing Cologuard, but Evaluate Vantage says lack of improved sensitivity for pre-cancerous lesions is disappointing:

https://finance.yahoo.com/news/next-generation-cologuard-test-demonstrates-200500387.html

https://www.evaluate.com/vantage/articles/news/trial-results/exacts-next-gen-cancer-screen-beats-original

The new version of Cologuard won’t be commercially available until 2024.